BTG (Bio-Technology General) starts imaging agent trials:
This article was originally published in Clinica
Executive Summary
Bio-Technology General will begin Canadian trials of its agent for imaging potentially dangerous blood clots in deep-vein thrombosis. Fibrimage, a Technetium-99m radiopharmaceutical, is based on a recombinant polypeptide with high binding affinity for fibrin and the primary component of venous thrombus. The New Jersey-based company said the trial, involving at least 48 patients, would be completed before the end of the year.